Metraipolis › archive › dc_da0e6d2ed1d4
Efficacy and Safety Analysis of Triple Therapy (Pabolizumab+Cryoablation+Renvastinib) for Patients with Unresectable Hepatocellular Carcinoma (uHCC) — Europe PMC PMID:41778426
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41778426
- DOI
- 10.34172/aim.34630
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T15:55:28.666Z
- SHA-256 of the archived text
02664b9e53827d86a58802a6c643796e1ed552a88dbcc7d318d792512a94c211- Stable URL of this page
https://metraipolis.com/documento/dc_da0e6d2ed1d4
How to cite
Efficacy and Safety Analysis of Triple Therapy (Pabolizumab+Cryoablation+Renvastinib) for Patients with Unresectable Hepatocellular Carcinoma (uHCC) — Europe PMC PMID:41778426 — Europe PMC (en), https://europepmc.org/article/MED/41778426 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_da0e6d2ed1d4 (Metraipolis archive dc_da0e6d2ed1d4, sha256 02664b9e53827d86a58802a6c643796e1ed552a88dbcc7d318d792512a94c211)
BibTeX
@misc{dcda0e6d2ed1d4,
title = {Efficacy and Safety Analysis of Triple Therapy (Pabolizumab+Cryoablation+Renvastinib) for Patients with Unresectable Hepatocellular Carcinoma (uHCC) — Europe PMC PMID:41778426},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41778426},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_da0e6d2ed1d4; sha256 02664b9e53827d86a58802a6c643796e1ed552a88dbcc7d318d792512a94c211},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41778426. Agents can read the archived copy with the MCP tool read_document.